The Glaxo SmithKline Pharma (GSK Pharma) stock, which has been on the rise since mid-December (when its foreign parent announced plans to raise its stake in the company), hit an all-time high of Rs 3,054.4 on Monday.
The share price of GlaxoSmithKline Pharma (GSK Pharma) hit 52-week high at Rs 3054.4 apiece on Mondaydue to investors' pick on expectations for a further upsurge towards the openoffer price of Rs 3100 apiece.
GlaxoSmithKline will stop paying doctors to promote its products at events and remove individual sales targets for its marketing staff in a first for the drugs industry looking to recover from scandals over improper sales practices.
British pharmaceutical, biologics, vaccine and consumer healthcare group, GlaxoSmithKline Plc, has initiated an open offer to increase stake in its publicly listed subsidiary in India, GlaxoSmithKline Pharmaceuticals Ltd.
Glaxosmithkline Pharma plc has initiated an open offer to buy 20,609,774 shares, representing 24.33% of the total voting share capital, from the public shareholders of its India-listed arm – GSK Pharma – for Rs 3,100 per share.
British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.
"It has come to our knowledge that in the major pockets of the country our products are not being purchased by the traders from September 15, 2013. On account of the above, sales of the company continue to be affected," the company said in a
The consumer arm of British pharma major, GlaxoSmithKline (GSK), is extending its popular antacid Eno, used to cure acidity and other gastric issues, into tablets and liquids in a bid to take on rivals such as Digene from Abbott and Gelusil from Pfizer.
GlaxoSmithKline Plc, the drugmaker being investigated in China for alleged bribery, is the latest foreign company to come under government scrutiny as Premier Li Keqiang tries to assuage anger over consumer safety breaches.
India's GlaxoSmithKline Pharmaceuticals is down 4.3 per cent after Nomura downgraded the stock by a notch to "reduce" from "neutral", citing the impact from the government's recent price controls and decreasing likelihood of an open